These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6805179)

  • 1. [Synthetic polymers as stimulators and prolonging agents of the immune action of the brucellosis protective antigen].
    Dranovskaia EA; Ignatov PE
    Zh Mikrobiol Epidemiol Immunobiol; 1982 Mar; (3):69-73. PubMed ID: 6805179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of brucellosis protective antigen on the phagocytic activity of the cells].
    Chernysheva MI; Dranovskaia EA
    Zh Mikrobiol Epidemiol Immunobiol; 1978 Apr; (4):80-4. PubMed ID: 99925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunobiological properties of the protective brucellosis antigen].
    Dranovskaia EA; Vershilova PA; Grekova NA
    Zh Mikrobiol Epidemiol Immunobiol; 1974 Sep; (9):66-70. PubMed ID: 4216217
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of a Brucella protein-polysaccharide antigen for the allergen diagnosis of brucellosis].
    Dzhasybaeva TS; SUkhodoeva GS; Vershilova PA; Dranovskaia EA; Kasymova KhA
    Zh Mikrobiol Epidemiol Immunobiol; 1985 May; (5):83-6. PubMed ID: 3929503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunopotentiation of live brucellosis vaccine by adjuvants.
    Denisov AA; Korobovtseva YS; Karpova OM; Tretyakova AV; Mikhina LV; Ivanov AV; Salmakov KM; Borovick RV
    Vaccine; 2010 Oct; 28 Suppl 5():F17-22. PubMed ID: 20362624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative study of the safety, reactogenicity and antigenic activity of chemical and live brucellosis vaccines in a controlled epidemiological trial].
    Sumarokov AA; Karinskaia GA; Dranovskaia EA; Vershilova PA; Sharipov MK
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Feb; (2):58-63. PubMed ID: 6424361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunogenic properties of brucella protective antigen upon revaccination].
    Dranovskaia EA; Vershilova PA
    Zh Mikrobiol Epidemiol Immunobiol; 1976; (12):94-9. PubMed ID: 828826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phenol-insoluble vaccine against human brucellosis: evaluation of the immunogenic power in guinea pigs].
    Bolpe J; de Lapenta DF; García-Carrillo C
    Rev Inst Med Trop Sao Paulo; 1991; 33(1):23-7. PubMed ID: 1843392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenic properties of soluble antigens or whole cells of Brucella abortus strain 45/20 associated with immunoadjuvants. I. Soluble antigens.
    Woodard LF; Toone NM; McLaughlin CA
    Can J Comp Med; 1980 Oct; 44(4):453-5. PubMed ID: 6778599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PLGA (85:15) nanoparticle based delivery of rL7/L12 ribosomal protein in mice protects against Brucella abortus 544 infection: A promising alternate to traditional adjuvants.
    Singh D; Somani VK; Aggarwal S; Bhatnagar R
    Mol Immunol; 2015 Dec; 68(2 Pt A):272-9. PubMed ID: 26442664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Incorporation of the protective antigen of Brucella abortus into liposomes and the immunogenic properties of the antigen-containing liposomes].
    Kulikov VI; Kashkin KP; Dranovskaia EA
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Dec; (12):69-72. PubMed ID: 3937400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological evaluation of brucellosis: importance of species in antigen preparation.
    Devi SJ; Polt SS; Boctor FN; Peter JB
    J Infect Dis; 1987 Oct; 156(4):658-61. PubMed ID: 3114390
    [No Abstract]   [Full Text] [Related]  

  • 13. Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis.
    Mallick AI; Singha H; Khan S; Anwar T; Ansari MA; Khalid R; Chaudhuri P; Owais M
    Vaccine; 2007 Nov; 25(46):7873-84. PubMed ID: 17931756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.
    Al-Mariri A; Tibor A; Mertens P; De Bolle X; Michel P; Godefroid J; Walravens K; Letesson JJ
    Infect Immun; 2001 Aug; 69(8):4816-22. PubMed ID: 11447155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of the badger (Meles meles) to infection with Brucella abortus.
    Corbel MJ; Morris JA; Thorns CJ; Redwood DW
    Res Vet Sci; 1983 May; 34(3):296-300. PubMed ID: 6410474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of adjuvants on immune responses in cattle injected with a Brucella abortus soluble antigen.
    Dzata GK; Confer AW; Wyckoff JH
    Vet Microbiol; 1991 Sep; 29(1):27-48. PubMed ID: 1835213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant outer membrane protein 25c from Brucella abortus induces Th1 and Th2 mediated protection against Brucella abortus infection in mouse model.
    Paul S; Peddayelachagiri BV; Nagaraj S; Kingston JJ; Batra HV
    Mol Immunol; 2018 Jul; 99():9-18. PubMed ID: 29649688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunization of guinea-pigs and mice with a whole-culture extract of a smooth and a rough strain of Brucella abortus.
    Keppie J; Witt K; Smith H
    Br J Exp Pathol; 1972 Oct; 53(5):518-28. PubMed ID: 4628447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A screening ELISA for brucellosis in reindeer.
    Asbakk K; Gall D; Stuen S
    Zentralbl Veterinarmed B; 1999 Nov; 46(9):649-57. PubMed ID: 10605375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immune response of guinea pigs to combined action of brucella vaccine and homologous lysed antigen].
    Rementsova MM; Shin NG; Usmanova FI
    Zh Mikrobiol Epidemiol Immunobiol; 1980 Mar; (3):72-5. PubMed ID: 6774529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.